Literature DB >> 24576895

Hyoscine N-butylbromide (Buscopan®) in the treatment of acute ureteral colic: what is the evidence?

George Papadopoulos1, Andreas Bourdoumis, Stefanos Kachrilas, Christian Bach, Noor Buchholz, Junaid Masood.   

Abstract

OBJECTIVE: To investigate the evidence for the use of hyoscine N-butylbromide (HBB) in the treatment of acute renal colic.
METHODS: A literature search was performed using the keywords 'hyoscine N-butylbromide', 'ureteral colic', 'spasmolytic', 'anticholinergic' and 'analgesia'. The articles were given the appropriate level of evidence according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence guidelines.
RESULTS: The analgesic effect of HBB as monotherapy is inferior to that of opioids and/or non-steroidal anti-inflammatory drugs (NSAIDs). It does provide an analgesic and antispasmodic effect, but not as long-lasting as NSAIDs. HBB does not serve as an adjunct to opioids. Furthermore, it does not facilitate passage of ureteral stones and has no effect on expulsion rate.
CONCLUSIONS: HBB is often used where urinary tract smooth muscle spasm is thought to be part of the pathophysiological process. According to the evidence, administration of HBB follows non-peer-reviewed protocols which are based on empiric recommendations. Its role is still unclear, as it appears to have no advantage when used as monotherapy over established forms of analgesia. There appears to be a time-dependent relation to pain reduction following parenteral administration, but this needs to be confirmed by more prospective randomized cohorts. 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24576895     DOI: 10.1159/000358015

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  7 in total

Review 1.  Evolving Guidance on Ureteric Calculi Management in the Acute Setting.

Authors:  Jonathan K Makanjuola; Sophie Rintoul-Hoad; Matthew Bultitude
Journal:  Curr Urol Rep       Date:  2016-03       Impact factor: 3.092

2.  Hyoscine N-Butylbromide for Preventing Propofol Injection Pain: A Randomized, Placebo-Controlled and Double-Blind Study.

Authors:  Mehmet Sargın; Mehmet Selçuk Uluer; Eyüp Aydoğan
Journal:  Med Princ Pract       Date:  2018-01-23       Impact factor: 1.927

3.  Evaluation of hyoscine N-butyl bromide efficacy on the prevention of catheter-related bladder discomfort after transurethral resection of prostate: a randomized, double-blind control trial.

Authors:  Golnar Sabetian; Farid Zand; Elham Asadpour; Mohammad Ghorbani; Pourya Adibi; Mohammad Mehdi Hosseini; Shahryar Zeyghami; Farzaneh Masihi
Journal:  Int Urol Nephrol       Date:  2017-08-14       Impact factor: 2.370

Review 4.  [S2k guidelines on diagnostics, therapy and metaphylaxis of urolithiasis (AWMF 043/025) : Compendium].

Authors:  T Knoll; T Bach; U Humke; A Neisius; R Stein; M Schönthaler; G Wendt-Nordahl
Journal:  Urologe A       Date:  2016-07       Impact factor: 0.639

Review 5.  Kidney stones.

Authors:  Saeed R Khan; Margaret S Pearle; William G Robertson; Giovanni Gambaro; Benjamin K Canales; Steeve Doizi; Olivier Traxer; Hans-Göran Tiselius
Journal:  Nat Rev Dis Primers       Date:  2016-02-25       Impact factor: 52.329

6.  The Effect of Hyoscine on Pain, Tenderness, and Rebound Tenderness in Patients with Appendicitis: Quasi-Interventional Study.

Authors:  Alireza Esmaeili; Vahideh Salimi; Naser Mohammad Karimi; Majid Hajimaghsoudi; Mahmoud Vakili; Ehsan Zarepur
Journal:  Bull Emerg Trauma       Date:  2018-10

7.  The BUSCOPAN study: a randomized-controlled non-inferiority trial of a continuous butylscopolamine infusion versus placebo in patients with a renal colic not responding to oral non-steroidal anti-inflammatory drugs.

Authors:  S Weltings; K T Buddingh; D C van Diepen; R C M Pelger; H Putter; M Rad; B M A Schout; H Roshani
Journal:  World J Urol       Date:  2020-09-19       Impact factor: 4.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.